Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H16O5 |
| Molecular Weight | 324.3273 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)C[C@@H](C1=CC=CC=C1)C2=C(O)C3=C(OC2=O)C=C(O)C=C3
InChI
InChIKey=SKFYEJMLNMTTJA-HNNXBMFYSA-N
InChI=1S/C19H16O5/c1-11(20)9-15(12-5-3-2-4-6-12)17-18(22)14-8-7-13(21)10-16(14)24-19(17)23/h2-8,10,15,21-22H,9H2,1H3/t15-/m0/s1
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites. | 1995 Jun |
|
| Simultaneous measurement of S-warfarin, R-warfarin, S-7-hydroxywarfarin and R-7-hydroxywarfarin in human plasma by liquid chromatography-tandem mass spectrometry. | 2010 Jun 5 |
|
| A chiral HPLC-MS/MS method for simultaneous quantification of warfarin enantiomers and its major hydroxylation metabolites of CYP2C9 and CYP3A4 in human plasma. | 2014 |
|
| Warfarin Metabolites in Patients Following Cardiac Valve Implantation: A Contribution of Clinical and Genetic Factors. | 2015 Jun |
|
| Delayed de-induction of CYP2C9 compared to CYP3A after discontinuation of rifampicin: Report of two cases . | 2017 May |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
790295572A
Created by
admin on Sat Dec 16 08:19:17 GMT 2023 , Edited by admin on Sat Dec 16 08:19:17 GMT 2023
|
PRIMARY | |||
|
54692246
Created by
admin on Sat Dec 16 08:19:17 GMT 2023 , Edited by admin on Sat Dec 16 08:19:17 GMT 2023
|
PRIMARY | |||
|
63740-81-8
Created by
admin on Sat Dec 16 08:19:17 GMT 2023 , Edited by admin on Sat Dec 16 08:19:17 GMT 2023
|
PRIMARY |
PARENT (METABOLITE)
SUBSTANCE RECORD
